This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include KALA, Graham, Arq and Hawkins
by Zacks Equity Research
KALA, GHM, ARQ, and HWKN are drawing investor attention after fresh analyst coverage highlights improving outlooks.
Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility
by Shrabana Mukherjee
New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.
KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
KALA BIO (KALA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
KALA BIO (KALA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
KALA BIO (KALA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
KALA BIO (KALA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
KALA BIO (KALA) delivered earnings and revenue surprises of -58.60% and 100%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
by Zacks Equity Research
Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.
VYNE Gains on Preclinical Data for IPF Candidate
by Zacks Equity Research
VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.
Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag
by Zacks Equity Research
Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.
Gamida Cell (GMDA) Surges on FDA Approval for Omisirge
by Zacks Equity Research
Gamida Cell's (GMDA) shares surge as it receives FDA approval for Omisirge, an allogeneic cell therapy for blood cancer patients.
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
by Zacks Equity Research
Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.
Alvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate
by Zacks Equity Research
Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429
by Zacks Equity Research
Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug
by Zacks Equity Research
Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-onset type 1 diabetes.
Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.
KALA Up on Fast Track Designation to Lead Ocular Candidate
by Zacks Equity Research
KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects.
Humacyte (HUMA) Completes Enrollment in HAV Technology Study
by Zacks Equity Research
Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human acellular vessel product for vascular access in hemodialysis patients.
Panbela (PBLA) Regains Flynpovi Rights to Treat FAP
by Zacks Equity Research
Panbela (PBLA) shares surge as it regains rights to develop and commercialize Flynpovi for the familial adenomatous polyposis treatment.
Apellis (APLS) Stock Up 50% in Three Months: Here's Why?
by Zacks Equity Research
Apellis (APLS) stock rises 50% in the past three months owing to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake in its first marketed product, Empaveli, also contributed to the surge.
Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data
by Zacks Equity Research
Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.
Palisade (PALI) Enrolls First Patient in LB1148 Study in China
by Zacks Equity Research
Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.
Kala Pharmaceuticals (KALA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Kala Pharmaceuticals (KALA) closed the most recent trading day at $13.71, moving -1.37% from the previous trading session.
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment
by Zacks Equity Research
InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.
CRISPR (CRSP) & Vertex Complete BLA Submission for Exa-Cel
by Zacks Equity Research
CRISPR (CRSP) and Vertex complete BLA submissions to the FDA for exa-cel for treating sickle cell disease and transfusion-dependent beta-thalassemia.